Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology/Epidemiology
  • Published:

Clinical Oncology/Epidemiology

Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers

Abstract

The aims of the present study were to characterise an assay for cAMP-binding proteins in ovarian cancer and then to measure levels in a series of tumours with a view to developing a potential prognostic indicator for this disease. Levels and types of binding proteins have been measured in cytosols from 50 ovarian tumours. Binding proteins were detected in all tumours but, as calculated from Scatchard analysis, binding levels ranged from 267 to 12,037 fmol per mg of cytosol protein (mean value of 4248 fmol mg-1). Dissociation constants of binding varied between 0.4 x 10(-8) and 5.9 x 10(-8) (mean value 2.3 x 10(-8)). Types of binding protein were detected by incubation with the photoaffinity ligand 8-N3-[32P]cAMP, followed by polyacrylamide gel electrophoresis and autoradiography. Labelled proteins with molecular weights of 52, 48, 43, 39 and 37 kDa were identified in the cytosols. The proportion and pattern of bands detected varied between different cytosols. The significance of these findings awaits clinical follow-up of the patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramage, A., Burns, D. & Miller, W. Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers. Br J Cancer 69, 186–190 (1994). https://doi.org/10.1038/bjc.1994.32

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/bjc.1994.32

Search

Quick links